

## Q1 INVESTOR WEBINAR

- **PYC will hold an investor webinar on Friday 28 March 2025 at 8:00am AWST/11:00am AEST to provide an update on each of the Company's pipeline programs and their respective objectives for 2025**

### **PERTH, Australia and SAN FRANCISCO, California – 21 March 2025**

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) will hold an investor webinar to update shareholders on progress made in Q1 2025 on Friday 28 March 2025 at 8:00am AWST (11:00am AEST).

Shareholders are invited to register for the webinar via the link below:

[https://us02web.zoom.us/webinar/register/WN\\_-Z6AW35iQ\\_-twvJrYDRTJA](https://us02web.zoom.us/webinar/register/WN_-Z6AW35iQ_-twvJrYDRTJA)

After registering, you will receive a confirmation email containing information about joining the webinar.

This announcement was approved for release by the CEO of PYC Therapeutics Limited.

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

### **PYC's drug development programs**

#### **Retinitis Pigmentosa type 11**

- A blinding eye disease of childhood affecting 1 in every 100,000 people<sup>2</sup>
- Currently progressing through phase 1/2 clinical trials with preparation under way for a potentially registrational trial to commence in 2025<sup>3</sup>

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.20222232>

<sup>2</sup> Sullivan L, et al. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2006;47(10):4579-88

<sup>3</sup> Subject to the risks outlined in the Company's ASX announcement of 14 March 2024

## **Autosomal Dominant Optic Atrophy**

- A blinding eye disease of childhood affecting 1 in every 35,000 people<sup>4</sup>
- Currently progressing through phase 1/2 clinical trials with human safety and efficacy read-outs anticipated in 2025<sup>5</sup>

## **Autosomal Dominant Polycystic Kidney Disease**

- A chronic kidney disease affecting 1 in every 1,000 people<sup>6</sup> that leads to renal failure and the need for organ transplantation in the majority of patients
- Currently progressing through phase 1a/1b clinical trials with human safety and efficacy data anticipated throughout 2025 and 2026<sup>7</sup>

## **Phelan McDermid Syndrome**

- A severe neurodevelopmental disorder affecting 1 in every 10,000 people<sup>8</sup>
- PYC will initiate Investigational New Drug (IND)-enabling studies in 2025 to facilitate progression into human trials in 2026

For more information, visit [pyctx.com](https://pyctx.com), or follow us on LinkedIn and Twitter.

## **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

## **CONTACTS:**

**INVESTORS and MEDIA**  
[investor@pyctx.com](mailto:investor@pyctx.com)

<sup>4</sup> Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038

<sup>5</sup> Subject to the risks outlined in the Company's ASX announcement of 14 March 2024

<sup>6</sup> Harris PC, Torres VE. Polycystic Kidney Disease, Autosomal Dominant. 2002 Jan 10 [Updated 2022 Sep 29]. In: Adam MP, Feldman J, Mirzaz GM, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2023.

<sup>7</sup> Subject to the risks outlined in the Company's ASX announcement of 14 March 2024

<sup>8</sup> Phelan-McDermid Syndrome Foundation. <https://pmsf.org/about-pms/>